Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.33 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | F2R | P25116 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1730548 | 0.85 | KDM4E (0.32) | KDM4EMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL14449091 | 0.83 | F2R (0.41) | ACHEKDM4EMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1729930 | 0.82 | KDM4E (0.33) | KDM4EMAPTRAB9ASMN1; SMN2NPC1 | |
| Bromide SCHEMBL1729985 | 0.82 | RAB9A (0.31) | KDM4EMAPTRAB9ANPC1KMT2A | |
| Bromide SCHEMBL5486542 | 0.81 | F2R (0.36) | ACHEKDM4EMAPTRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL1732146 | 0.80 | F2R (0.34) | KDM4EMAPTRAB9ASMN1; SMN2NPC1 | |
| Bromide SCHEMBL1729690 | 0.79 | F2R (0.35) | KDM4EMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL1730661 | 0.79 | F2R (0.36) | KDM4EMAPTRAB9ASMN1; SMN2NPC1 | |
| Bromide SCHEMBL1730802 | 0.79 | F2R (0.37) | KDM4EMAPTRAB9ANPC1F2R | |
| Bromide SCHEMBL1730674 | 0.79 | F2R (0.35) | ACHEKDM4EMAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1391451-B1 | 2-IMINOPYRROLIDINE DERIVATES | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| EP-1954321-B1 | METHOD OF DYNAMIC NUCLEAR POLARISATION (DNP) USING A TRITYL RADICAL AND A PARAMAGNETIC METAL ION | GE HEALTHCARE AS (NO) | 2011-11-23 | — | — | EP | disclosed |
| WO-2009150211-A1 | DNP POLARISER AND METHOD OF PRODUCING A HYPERPOLARISED SELECTED MATERIAL | GE HEALTHCARE LIMITED (GB) | 2009-12-17 | — | — | WO | disclosed |
| EP-1954321-A2 | METHOD OF DYNAMIC NUCLEAR POLARISATION (DNP) USING A TRITYL RADICAL AND A PARAMAGNETIC METAL ION | GE Healthcare AS (NO) | 2008-08-13 | — | — | EP | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| WO-2007064226-A2 | METHOD OF DYNAMIC NUCLEAR POLARISATION (DNP) USING A TRITYL RADICAL AND A PARAMAGNETIC METAL ION | GE HEALTHCARE AS (NO) | 2007-06-07 | — | — | WO | disclosed |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1391451-A1 | 2-IMINOPYRROLIDINE DERIVATES | Eisai Co., Ltd. (JP) | 2004-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | ACHE 2759/4885KDM4E 3161/4885MAPT 3483/4885 |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | ACHE 2748/4885KDM4E 3132/4885MAPT 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.